Financials IRLAB Therapeutics AB

Stocks

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-07-07 EDT			5-day change	1st Jan Change
1.394 ^SEK	+6.41%		+12.42%	-29.24%

06-30	IRLAB Therapeutics AB Approves Election of Janne Backman as Vice Chairperson of the Board of Directors	CI
06-30	IRLAB Therapeutics Rights Issue Raises About SEK 68 Mln	RE

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	207.8	61.14	5.678	94.63	57.46	102	141.8
Change	-	-70.58%	-90.71%	1,566.57%	-39.28%	77.51%	39.02%
EBITDA ¹	56.05	-108.3	-176.4	-70.53	-89.08	-27.6	37.3
Change	-	-293.28%	-62.88%	60.03%	-26.3%	69.02%	235.14%
EBIT ¹	52.58	-113.1	-180.8	-75.11	-93.4	-31.6	33.3
Change	-	-315.14%	-59.81%	58.45%	-24.35%	66.17%	205.38%
Interest Paid	-0.796	-0.297	2.927	-8.018	-16.61	-	-
Earnings before Tax (EBT)	51.78	-113.4	-177.8	-83.13	-110	-	-
Change	-	-319.01%	-56.82%	53.26%	-32.34%	-	-
Net income ¹	51.78	-113.4	-177.8	-83.13	-110	-32.6	33.3
Change	-	-319.01%	-56.82%	53.26%	-32.34%	70.37%	202.15%
Announcement Date	2/23/22	2/23/23	2/7/24	2/12/25	2/25/26	-	-

¹SEK in Million

Estimates

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027
Net Debt	-402	-253	-111	-63.4	-	-	-
Change	-	37.06%	56.13%	42.88%	-	-	-
Announcement Date	2/23/22	2/23/23	2/7/24	2/12/25	2/25/26	-	-

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025
CAPEX ¹	0.394	0.708	2.876	0.293	0.199	-
Change	-	79.7%	306.21%	-89.81%	-32.08%	-
Free Cash Flow (FCF) ¹	-55.24	69.69	-103.6	-99.98	-38.77	-18.3
Change	-	226.16%	-248.61%	3.46%	61.23%	52.8%
Announcement Date	4/15/21	4/8/22	4/29/24	4/29/24	4/25/25	4/29/26

¹SEK in Million

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	26.98%	-177.2%	-3,107.59%	-74.53%	-155.02%	-27.06%	26.3%
EBIT Margin (%)	-	25.3%	-185.01%	-3,183.6%	-79.38%	-162.54%	-30.98%	23.48%
EBT Margin (%)	-	24.92%	-185.5%	-3,132.07%	-87.85%	-191.45%	-	-
Net margin (%)	-	24.92%	-185.5%	-3,132.07%	-87.85%	-191.45%	-31.96%	23.48%
FCF margin (%)	-	-	-	-2,908.65%	-69.52%	-	-	-
FCF / Net Income (%)	-	-	-	92.87%	79.14%	-	-	-
Profitability
ROA	-19.77%	7.8%	-17.59%	-44.96%	-29.11%	-39.27%	-	-
ROE	-34.61%	13.86%	-32.86%	-87.48%	-112.03%	-347.29%	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	0.34%	4.7%	5.16%	-	-	-	-
CAPEX / EBITDA (%)	-	1.26%	-2.65%	-0.17%	-	-	-	-
CAPEX / FCF (%)	-	-	-	-0.18%	-	-	-	-
Items per share
Cash flow per share ¹	5.353	7.766	4.873	2.146	1.29	0.9637	-	-
Change	-	45.08%	-37.25%	-55.97%	-39.88%	-25.3%	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	6.723	7.72	5.607	2.232	0.6292	0.3617	-	-
Change	-	14.83%	-27.37%	-60.2%	-71.81%	-42.52%	-	-
EPS ¹	-1.922	1	-2.188	-3.429	-1.603	-1.642	-	-
Change	-	152.02%	-318.8%	-56.71%	53.26%	-2.45%	-	-
Nbr of stocks (in thousands)	51,748	51,748	51,868	51,868	51,868	84,938	-	-
Announcement Date	4/15/21	4/8/22	4/29/24	4/29/24	4/25/25	4/29/26	-	-